Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients.
Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights.
As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
On July 2, 2019, the PMPRB Steering Committee on the
Modernization of Price Review Process Guidelines released its final report summarizing its deliberations in
providing stakeholder feedback on the PMPRB’s proposed new
framework for regulation of the prices of patented medicines. PMPRB
officials presented a draft of this report to the Steering
Committee on May 13, 2019 (see our previous report here). The PMPRB will publish draft guidelines
for public consultation once the Board has had an opportunity to
review the Steering Committee’s final report and following
final publication of the amended Patented Medicines
Regulations.
The preceding is intended as a timely update on Canadian
intellectual property and technology law. The content is
informational only and does not constitute legal or professional
advice. To obtain such advice, please communicate with our offices
directly.
